Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.
By David R. Holmes III, Saibal Kar, M. Price, B. Whisenant, H. Sievert, S. Doshi, K. Huber, Vivek Y. Reddy. Journal of the American College of Cardiology, 2014
1,676 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/857f07cdeb697f4904b7bfddd1cc1d103bfda8f3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- A. Boehme
- Mitchell S. V. Elkind
- Charles C. Esenwa
Citations in the corpus
- Stroke Risk Factors, Genetics, and Prevention (2017, methodology): “In both trials, the Watchman device was noninferior in efficacy for the prevention of ischemic stroke.(274,275) Pericardial effusion, periprocedural stroke, and device embolization accounted for the major complications.”
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. (2016, neutral): “man LAA Closure Device In Patients with AF Versus Long Term Warfarin Therapy trial)].(449) – 451 In these data sets, LAA occlusion was non-inferior to VKA treatment for the prevention of stroke in AF patients with moderate stroke risk, with a possibility of lower bleeding rates in the patients who c”